BiologicalDrug
gp100:209-217(210M) Peptide Vaccine clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 1999
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 1999 (2)
| Year | Studies |
|---|---|
| 1999 | 2 |
| 2002 | 1 |
| 2003 | 1 |
| 2006 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 4
National Cancer Institute (NCI) (3) · University of Southern California (1) · Bristol-Myers Squibb (1)
Often tested with
Tested in the same studies.
MART-1 Antigen (1) · Tyrosinase Peptide (1) · Incomplete Freund's adjuvant (1) · Interleukin-2 (1) · MART-1:26-35(27L) Peptide Vaccine (1) · Fludarabine (1) · Cyclophosphamide (1) · Filgrastim (1)
Studies
Open first, then newest update. How each study uses gp100:209-217(210M) Peptide Vaccine is read from its arms, and is right about nine times in ten.
Testing it · 5
- Vaccine Therapy in Treating HLA-A2 Positive Patients With MelanomaCompletedPhase 2National Cancer Institute (NCI)NCT00003895Written as gp100:209-217(210M)
- Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By SurgeryCompletedPhase 1National Cancer Institute (NCI)NCT01989559Written as gp100:209-217(210M) Peptide Vaccine
- Vaccine Therapy in Treating Patients With Metastatic MelanomaCompletedPhase 2University of Southern CaliforniaNCT00334776Written as gp100:209-217(210M) peptide vaccine
- Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV MelanomaWithdrawnPhase 2Bristol-Myers SquibbNCT00357461Written as gp100:209-217(210M) peptide vaccine
- Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic MelanomaCompletedPhase 2National Cancer Institute (NCI)NCT00001832Written as gp100:209-217 (210M)
Given in every arm · 3 — gp100:209-217(210M) Peptide Vaccine is usual care beside what is tested
- Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558CompletedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT01176461Written as gp100:209-217(210M)
- Vaccine Plus Interleukin-2 in Treating Patients With Advanced MelanomaCompletedPhase 2National Cancer Institute (NCI)NCT00005949Written as gp100:209-217(210M) peptide vaccine
- Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk MelanomaCompletedPhase 2National Cancer Institute (NCI)NCT00273910Written as gp100:209-217 (210M)